SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Bio NC
Clinical Catch-Up: October 25-29
Yet another busy week for clinical trial news. Here’s a look.
October 29, 2021
 · 
12 min read
 · 
Mark Terry
Courtesy of AbbVie, Inc.
Drug Development
Alnylam and AbbVie Each Reveal Influential Phase III Results
After first reporting that its investigational RNAi drug vutrisiran hit its 9-month Phase III endpoints, Alnylam announced it continues to demonstrate positive results at the 18-month mark.
October 29, 2021
 · 
4 min read
 · 
Alex Keown
TARPEYO is the first FDA-approved drug for immunog
Drug Development
FDA OKs Gilead’s Pediatric HIV Treatment and Boehringer’s Humira Biosimilar
The U.S. FDA greenlit a new indication for Gilead Sciences’ drug Biktarvy for pediatric patients with HIV who are virologically suppressed or new to antiretroviral therapy.
October 18, 2021
 · 
3 min read
 · 
Alex Keown
Policy
Opioid Fight Clocks Another Win as Drug Distributors Reach Settlements
Teva Pharmaceuticals reached a $15 million agreement with the state of Louisiana to settle claims against the company over its marketing of opioid products.
September 30, 2021
 · 
3 min read
 · 
Alex Keown
AbbVie_© AbbVie Inc. All rights reserved.
Drug Development
New Relief for Migraine Sufferers as FDA Approves AbbVie’s Atogepant
Qulipta is the first calcitonin gene-related peptide (CGRP) receptor antagonist specifically developed for this indication.
September 29, 2021
 · 
2 min read
 · 
Alex Keown
Business
A Fundamentally Different View into Complex Neurological Diseases
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.
September 29, 2021
 · 
6 min read
 · 
Heather McKenzie
Business
Alpine, Anjarium and Amolyt Net New Funds on Lucrative Investment Day
The proceeds will be used for the companies’ growth, to help develop their platforms and advance their pipelines.
September 16, 2021
 · 
3 min read
 · 
Alex Keown
Courtesy of AbbVie, Inc.
Business
AbbVie, REGENXBIO Partner on Potential One-Time Treatment for Wet AMD
The drug, called RGX-314, is a possible one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal diseases.
September 13, 2021
 · 
2 min read
 · 
Vanessa Doctor, RN
SKYRIZI is the new option for psoriatic arthritis.
Policy
FDA Crackdown on JAK Drug Class Unwelcome News for Pharma Giants
Henceforth, all JAK-inhibiting drugs like AbbVie’s Rinvoq, Pfizer’s Xeljanz, and Lilly’s Olumiant, have been ordered to include a warning label on the medicine to be sold in the U.S.
September 2, 2021
 · 
4 min read
 · 
BioSpace Editorial Staff
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Drug Development
AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress
June 11, 2022
 · 
9 min read
BioMidwest
AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients
June 10, 2022
 · 
8 min read
BioMidwest
New Data Demonstrates AbbVie’s VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment
June 10, 2022
 · 
15 min read
Job Trends
AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® (AHS) Annual Scientific Meeting
June 7, 2022
 · 
23 min read
Drug Development
AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
June 1, 2022
 · 
17 min read
BioMidwest
Unlocking the next level of protein degradation
May 31, 2022
 · 
3 min read
Drug Development
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis
May 27, 2022
 · 
16 min read
Drug Development
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn’s Disease
May 27, 2022
 · 
10 min read
BioMidwest
AbbVie to Present at the Bernstein 38th Annual Strategic Decisions Conference
May 25, 2022
 · 
1 min read
BioMidwest
AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress
May 24, 2022
 · 
27 min read
Load More